Evercore ISI lowers D-Wave Quantum stock price target on valuation

Evercore ISI cut its price target on D-Wave Quantum to $37 from $42 while keeping an Outperform rating, and Mizuho and Canaccord also trimmed targets to $29 and $41, respectively. Q1 2026 revenue was $2.9 million, below the $4.1 million consensus, but EPS loss of $0.05 beat the expected $0.08 loss and bookings rose 149% quarter-over-quarter to about $33.4 million. Management still expects 2 to 3 quantum annealing system bookings in 2026 and plans manufacturing investments in 2027 to support growth.

Analysis

The market is still pricing QBTS as a story stock with a long-duration growth option, but the latest revisions suggest the next re-rating hinge is not technological progress per se — it is conversion of bookings into repeatable, financeable deployments. That matters because a company with high gross margins but lumpy system revenue can look deceptively cheap or expensive depending on whether investors anchor on annualized bookings or on near-term revenue misses; the gap between those two will likely widen over the next 2-4 quarters.

The bigger second-order effect is competitive: if QBTS can credibly signal multi-system annual bookings, it forces adjacent quantum names to justify similar commercial traction rather than pure technical differentiation. That should keep capital concentrated in the few names with visible enterprise use-case expansion, while weaker players may face multiple compression even in a favorable sector tape. The manufacturing expansion in 2027 also creates an execution bottleneck risk: any delay in capacity buildout would be read as evidence that demand outran operational readiness, which is usually when growth stocks de-rate fastest.

Consensus appears to underweight how fragile the current narrative is to one or two quarterly prints. A single absent system sale already showed that headline bookings can coexist with weak recognized revenue, so the next catalyst is not just another contract announcement but proof that customers are moving from pilot to production and that timing is stable. If that bridge is not crossed by mid-2026, the market may start discounting these estimates heavily, because nine-year discounted terminal models are extremely sensitive to even modest slippage in adoption timing.

Key Decisions for Investors

• Avoid chasing QBTS after estimate-driven target cuts; wait for a post-earnings pullback or a confirmed system-booking catalyst before initiating longs. Risk/reward is poor here because the stock is trading on distant terminal value while near-term revenue remains volatile.
• For tactical upside, buy QBTS 3-6 month call spreads only on a pullback into the low-20s or below, targeting a move back toward the high-20s/low-30s if another commercial system booking is announced. Cap risk with defined premium; this is a catalyst trade, not a hold-through-all-volatility position.
• Pair trade: long QBTS vs short a weaker quantum/early-stage innovation peer basket if available, betting that capital consolidates around the name with the clearest enterprise traction. Hold 1-2 quarters and cut if QBTS misses another revenue conversion milestone.
• If already long QBTS, trim 25-50% into strength ahead of the next quarterly print and keep the remainder as a venture-style optionality position. The key risk is a continued bookings/revenue mismatch that can compress the multiple quickly.
• Watch for confirmation that 2026 bookings become repeatable, not just one-off deals; if that pattern emerges, re-enter aggressively on any post-announcement consolidation because the market will likely shift from skepticism to scarcity premium.